Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) Return on Equity (2016 - 2025)

Historic Return on Equity for Ocular Therapeutix (OCUL) over the last 12 years, with Q4 2025 value amounting to 0.58%.

  • Ocular Therapeutix's Return on Equity fell 800.0% to 0.58% in Q4 2025 from the same period last year, while for Dec 2025 it was 0.58%, marking a year-over-year decrease of 800.0%. This contributed to the annual value of 0.54% for FY2025, which is 2700.0% up from last year.
  • Per Ocular Therapeutix's latest filing, its Return on Equity stood at 0.58% for Q4 2025, which was down 800.0% from 0.88% recorded in Q3 2025.
  • Ocular Therapeutix's Return on Equity's 5-year high stood at 0.3% during Q2 2024, with a 5-year trough of 16.05% in Q3 2023.
  • Moreover, its 5-year median value for Return on Equity was 0.94% (2021), whereas its average is 2.49%.
  • Within the past 5 years, the most significant YoY rise in Ocular Therapeutix's Return on Equity was 1244500bps (2021), while the steepest drop was -329600bps (2021).
  • Over the past 5 years, Ocular Therapeutix's Return on Equity (Quarter) stood at 0.97% in 2021, then plummeted by -115bps to 2.08% in 2022, then grew by 13bps to 1.81% in 2023, then surged by 73bps to 0.49% in 2024, then decreased by -17bps to 0.58% in 2025.
  • Its Return on Equity was 0.58% in Q4 2025, compared to 0.88% in Q3 2025 and 0.78% in Q2 2025.